Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17016707 | 0.81 | MAP4K4 (0.44) | EGLN1CLK1CLK2DYRK1ADYRK2 | |
| SCHEMBL18263141 | 0.81 | FYN (0.57) | EGLN1CLK1CLK2DYRK1ADYRK2 | |
| SCHEMBL17016659 | 0.81 | EGLN1 (0.48) | EGLN1CLK1CLK2DYRK1ADYRK2 | |
| SCHEMBL15577495 | 0.76 | EGLN1 (0.55) | EGLN1MAP4K4CA3CA6CA9 | |
| SCHEMBL11467795 | 0.74 | NPC1 (0.46) | EGLN1CLK1CLK2DYRK1ADYRK2 | |
| SCHEMBL31168607 | 0.73 | — | — | |
| SCHEMBL1005535 | 0.70 | ERCC1 (0.50) | CLK1CLK2DYRK1ADYRK2CLK4 | |
| SCHEMBL7001102 | 0.69 | HSD17B1 (0.56) | XDHSLC22A12ESR2 | |
| SCHEMBL31402889 | 0.69 | HSD17B1 (0.56) | XDHSLC22A12ESR2 | |
| SCHEMBL13854089 | 0.69 | PDGFRB (0.51) | MAP4K4FYNPDGFRBPDGFRAGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-20 | — | — | US | disclosed |
| US-9573938-B2 | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2014043252-A2 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204083-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, P4HA1 | EGLN1 56/4885CLK1 4378/4885CLK2 4052/4885 |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, DHX15 | EGLN1 59/4885CLK1 4452/4885CLK2 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.